The Trouble With AVATAR $AVXL Blarcamesine Rett Syndrome

Evercore ISI December 2, 2021 First order of the day, Plateau in Blarcamesine therapetic effect, 1:57' into interviewBlarcamsine therapetic effect proportionaly to SIGMAR1 mRNA level in bloodRising the dosing levels first meets with plateau then with protective mechanism (antagonist)We can dose high without adverse effects even in spite plateauThe Glutomate/Gaba balance in Rett patients with … Continue reading The Trouble With AVATAR $AVXL Blarcamesine Rett Syndrome

Transcription Or Translation: Two Sides of Blarcamesine Rett Syndrome $AVXL $ACAD

It Seems Blarcamesine Can Works On Either Of These Or Both... The SIGMAR1 receptors agonists can work on either of these or both but at different optimal doses. In the Trascription Complex, reading of genes is affected or regulation of genes, and the familial form (genetic cause) of a disease like Alzheimer's can have a … Continue reading Transcription Or Translation: Two Sides of Blarcamesine Rett Syndrome $AVXL $ACAD

In Case You Miss It: AVATAR Is In Search of Perfect Dose. Everything Else Is Icing On The Cake. Blarcamesine $AVXL

A Remark Which Makes Sense Recently, Dr. Missling made a remark that when you overdose Blacamesine (or rather you can not overdose as...) the natral process by which autophagy runs shuts down or did I misunderstood what he meant, it just saturates? I used the word autophagy to concisely described the immensely varied therapeutic effects … Continue reading In Case You Miss It: AVATAR Is In Search of Perfect Dose. Everything Else Is Icing On The Cake. Blarcamesine $AVXL

Atuzaginstat and Epidemiology of Alzheimer’s Diseases $CRTX $AVXL

Headline Selloff... The first line of $CRTX PR said that primary edpoints have not been achieved and a 80% selloff commenced. On Wall Street deep thinking and considerations of nuances of medicine are dangerous things. Beefore we progress any further I suggest you read my post on epidemiology of dementia which references a British paper … Continue reading Atuzaginstat and Epidemiology of Alzheimer’s Diseases $CRTX $AVXL

What Next With Cortexyme’s Atuzaginstat?

Not All Patients Respond To Treatment With Atuzaginstat... This is the undebatable fact. But what it means that "not to reach the level of statistically significance"? It means that for the dose cohort the probaility of the dosed patients to have results like those in placebo cohorts is lower than 5%. The dispertion about the … Continue reading What Next With Cortexyme’s Atuzaginstat?

What To Expect from $CRTX and Atuzaginstat at CTAD 2021 $AVXL $SAVA

An Illustration.... X-axis is in weeks of dosing, y-axis is in MMSE points and the number 30 represents the highest score. HowI Got There.... I took the best four patients who never declined from the group of the Superperformers from phase 2a and calculated their baseline average and then their changes in time (weeks) on … Continue reading What To Expect from $CRTX and Atuzaginstat at CTAD 2021 $AVXL $SAVA

Why You Should Count On Cortexyme To Deliver The Alzheimer’s Drug! $CRTX

Jitters of The Biotech Investors and Their Cure In most PRs companies give some measure of improvement of patients, with the number of subject and the p-values. The certainty of the improvemnts are judged mostely throught the prism of p-values as it is a number with a threshold once attained a semblence of certainty is … Continue reading Why You Should Count On Cortexyme To Deliver The Alzheimer’s Drug! $CRTX

Can Blarcamesine Catch Up to Simufilam and Surpass it? $AVXL $SAVA $CTRX

This is the final installment of three parts in the same question. Two previous installments are; link: https://piotrpeterblog.com/2021/08/09/cassava-science-results-vs-anavex-life-sciences-projections-sava-avxl/ link: https://piotrpeterblog.com/2021/09/27/why-sava-simufilam-might-not-have-any-advantage-over-avxl-blarcamesine-sava-avxl-crtx-snpx/ The Proper Mix If we are to assess the chances of Blarcamesnie to better its results in Alzheimer's phase 2b/3 then first we have to list the known factors impacting the response of the patients. … Continue reading Can Blarcamesine Catch Up to Simufilam and Surpass it? $AVXL $SAVA $CTRX

Why $SAVA Simufilam Might Not Have Any Advantage Over $AVXL Blarcamesine $SAVA $AVXL $CRTX $SNPX

So called previous post link https://piotrpeterblog.com/2021/08/09/cassava-science-results-vs-anavex-life-sciences-projections-sava-avxl/ This post is rather a continuation of that post. $SAVA, The First in The Race Contender The share price of $SAVA has taken some beating over the alegations of, let's say it outloud, fraud. Nevertheless, the price has been staging some comeback. Either, due to short memory of the … Continue reading Why $SAVA Simufilam Might Not Have Any Advantage Over $AVXL Blarcamesine $SAVA $AVXL $CRTX $SNPX

Neurotrophic Factors In Curing Alzheimer’s and Other Neurodegenerative Diseases. $SNPX $AVXL $ATHA

When It Rains It Pours... We are witnessing outpouring of excellent phase 2 results from many corners of the Alzheimer's and neurodegenerative field. The question now is; who is the best bet? The capital behaves like a loose cannon ball on a ship in rough seas, swinging from one company to another. I am primarily … Continue reading Neurotrophic Factors In Curing Alzheimer’s and Other Neurodegenerative Diseases. $SNPX $AVXL $ATHA